ArticleClinical rheumatology2026
Association between serum carotenoid concentrations and risk of all-cause and cause-specific mortality in individuals with osteoarthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOsteoarthritis (OA) has been a major public health challenge. The role of non-negligible dietary factors in the development of OA and in mortality risk among OA patients is unclear. This study aims to investigate the associations of serum carotenoid levels with mortality in OA patients.
methodsWe analyzed data from 2051 OA patients in NHANES III. Mortality through December 31, 2019, was determined via the National Death Index. We assessed associations between carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lutein/zeaxanthin, lycopene) and mortality using cubic splines and Cox regression. Sensitivity and stratified analyses were performed.
resultsOverall, 942 deaths occurred during a median 12.58-year follow-up. Higher quartiles of all carotenoids (except lutein/zeaxanthin) were associated with lower all-cause mortality (hazard ratios and 95% confidence intervals: 0.53 [0.41, 0.67], 0.74 [0.59, 0.95], 0.75 [0.59, 0.96], and 0.66 [0.51, 0.86] for α-carotene, β-carotene, β-cryptoxanthin, and lycopene). BMI modified the relationship between β-carotene and mortality, showing a protective effect with BMI < 30 kg/m
conclusionHigher serum carotenoid levels are linked to reduced mortality. While suggesting potential benefits, carotenoid supplement use remains questionable due to possible antioxidant interactions and synergistic effects. Key Points • Higher quartiles of all carotenoids (except lutein/zeaxanthin) were related to lower all-cause mortality. • Elevated serum carotenoid levels were associated with a decreased risk of mortality.
Indexed as
Identifiers
41582266What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.